Arsenic reverses glioblastoma resistance to mTOR-targeted therapies

Cell Cycle. 2013 May 15;12(10):1473-4. doi: 10.4161/cc.24747. Epub 2013 Apr 22.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Arsenic Trioxide
  • Arsenicals / therapeutic use*
  • Brain Neoplasms / drug therapy*
  • Drug Resistance, Neoplasm
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / metabolism
  • Erlotinib Hydrochloride
  • Glioblastoma / drug therapy*
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Oxides / therapeutic use*
  • Quinazolines / therapeutic use
  • Signal Transduction
  • Sirolimus / therapeutic use
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Antineoplastic Agents
  • Arsenicals
  • Oxides
  • Quinazolines
  • Erlotinib Hydrochloride
  • MTOR protein, human
  • ErbB Receptors
  • TOR Serine-Threonine Kinases
  • Arsenic Trioxide
  • Sirolimus